EphA2 in Cancer: Molecular Complexity and Therapeutic Opportunities
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms252212191 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Lisa Toracchio und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Experimental Oncology, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy. Hauptthemen laut MEDLINE: Receptor, EphA2, Neoplasms. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 132 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health through the Executive Programme of Cooperation in the field of Science and Technology between Italy and the USA 2023-2025, Italian Ministry of Health through the Executive Programme of Cooperation in the field of Science and Technology between Italy and the USA 2023–2025.
Abstract (Originalsprache)
Erythropoietin-producing hepatocellular A2 (EphA2) is a member of the Eph tyrosine kinase receptor family that has been linked to various biological processes. In tumors, EphA2 overexpression is associated with noncanonical pathway activation, tumor progression, and a poor prognosis, which has emphasized its importance as a marker of malignancy. Studies on numerous cancer models have highlighted EphA2’s dual and often contradictory action, which can be attributed to EphA2′s interactions involving multiple pathways and different ligands, as well as the heterogeneity of the tumor microenvironment. In this review, we summarize the main mechanisms underlying EphA2 dysregulation in cancer, highlighting its molecular complexity. Then, we analyze therapies that have been developed over time to counteract its action. We discuss the limitations of the described approaches, emphasizing the fact that the goal of new options is high specificity without losing therapeutic efficacy. For this reason, immunotherapy or the emerging field of targeted protein degradation with proteolysis-targeting chimeras (PROTACs) may represent a promising solution that can be developed based on a deeper understanding of the molecular mechanisms sustaining EphA2 oncogenic activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Experimental Oncology, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy.
- Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, Department of Biology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA.
ORCID-Profile: Lisa Toracchio, Marianna Carrabotta, Caterina Mancarella, Andrea Morrione, Katia Scotlandi
Förderung
- Italian Ministry of Health through the Executive Programme of Cooperation in the field of Science and Technology between Italy and the USA 2023-2025
- Italian Ministry of Health through the Executive Programme of Cooperation in the field of Science and Technology between Italy and the USA 2023–2025
Zitieren
APA
Toracchio, L., Carrabotta, M., Mancarella, C., Morrione, A., & Scotlandi, K. (2024). EphA2 in Cancer: Molecular Complexity and Therapeutic Opportunities. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252212191
Vancouver
Toracchio L, Carrabotta M, Mancarella C, Morrione A, Scotlandi K. EphA2 in Cancer: Molecular Complexity and Therapeutic Opportunities. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252212191
BibTeX
@article{Toracchio2024,
author = {Toracchio, Lisa and Carrabotta, Marianna and Mancarella, Caterina and Morrione, Andrea and Scotlandi, Katia},
title = {EphA2 in Cancer: Molecular Complexity and Therapeutic Opportunities},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms252212191}
}
EUVIMED